| Assessment Status |
Awaiting response from Applicant |
| HTA ID |
23056 |
| Drug |
Pembrolizumab |
| Brand |
Keytruda® |
| Indication |
Pembrolizumab (Keytruda®) In combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS ≥1. |
| Rapid review commissioned |
07/09/2023 |
| Rapid review completed |
03/10/2023 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
01/11/2023 |
| Pre-submission consultation with Applicant |
05/12/2023 |
| Full submission received from Applicant |
02/05/2024 |
| Preliminary review sent to Applicant |
19/12/2024 |
